文献速递妇科

老年女性腹腔内化疗疗效与毒性特征的评估

Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
PubMed 文献 · Gynecol Oncol · 2017-06-02

本研究为单机构回顾性分析,纳入2000至2013年接受腹腔内化疗的IIA-IIIC期上皮性卵巢癌患者133例,其中<70岁100例、≥70岁33例。老年患者完成的化疗周期数较少(6.4 vs 5.8,p=0.002),但中位无进展生存期(27 vs 31个月)与总生存期(71 vs 62个月)无统计学差异,3/4级中性粒细胞减少在老年组更严重(82% vs 100%,p=0.04)。作者认为经选择的老年患者对腹腔内化疗耐受良好且有效,临床试验外可能使用不足。

要点

  • 老年组(≥70岁)完成腹腔内化疗周期数显著少于年轻组(6.4 vs 5.8,p=0.002)。
  • 两组中位无进展生存期(27 vs 31个月)与总生存期(71 vs 62个月)无统计学差异。
  • 老年组3/4级中性粒细胞减少发生率更高(82% vs 100%,p=0.04)。

核心结论

  • 尽管老年上皮性卵巢癌患者完成的腹腔内化疗周期数较少,其生存与年轻患者相当。
  • 本研究中的老年患者均来自临床试验,可能比一般老年人群更健壮。
  • 腹腔内化疗在经选择的老年患者中似乎耐受良好且有效,临床试验外可能使用不足。

研究设计与样本

  • 单机构回顾性综述,纳入2000至2013年诊断为IIA-IIIC期上皮性卵巢癌并接受腹腔内化疗的患者。
  • 共纳入133例患者,其中<70岁100例,≥70岁33例。
  • 提取临床病理特征并计算生存。

主要发现

  • 临床试验入组率在两组间相似。
  • 在入组临床试验的患者中,老年患者接受的化疗周期数在统计学上更少(6.4 vs 5.8,p=0.002),但剂量延迟(0.9 vs 0.7,p=0.72)和剂量调整(0.9 vs 0.36,p=0.11)相似。
  • 中位无进展生存期(27 vs 31个月)和中位总生存期(71 vs 62个月)无统计学差异。
  • 3/4级中性粒细胞减少在老年患者中显著更严重(82% vs 100%,p=0.04)。
  • ≥2级神经病变和其他非血液学毒性在年龄组间无差异。

临床怎么用

  • 作者认为腹腔内化疗在经选择的老年患者中似乎耐受良好且有效,临床试验外可能使用不足。

局限性

  • 本研究为单机构回顾性综述。
  • 本研究中的老年患者均来自临床试验,可能比一般老年人群更健壮。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intraperitoneal (IP) chemotherapy (CT) for treatment of epithelial ovarian cancer (EOC) has been shown to provide a substantial OS advantage. This study aims to compare the toxicity and benefits of IP CT in patients ≥70 with those <70. METHODS: We performed a single institution retrospective review of patients diagnosed with Stage IIA-IIIC EOC from 2000 to 2013 who received IP CT. Clinicopathologic characteristics were extracted, and survival was calculated. RESULTS: 133 patients were included with 100 pts. <70years old and 33 pts. ≥70years old. Clinical trial enrollment was similar despite age. In trial enrolled patients, older patients received statistically fewer cycles of therapy (6.4 vs 5.8, p=0.002) but had similar dose delays (0.9 vs 0.7, p=0.72), and modifications (0.9 vs 0.36, p=0.11). Median PFS (27 vs 31months) and OS (71 and 62months) were not statistically different. Grade 3/4 neutropenia was significantly worse in the older patients (82% vs 100%, p=0.04). Neuropathy grade ≥2 and other non-hematologic toxicities were not different between age groups. CONCLUSIONS: Despite completing fewer cycles of IP CT, older EOC patients had comparable survival to younger patients. The population of older patients receiving IP CT in this study were on clinical trial and likely to be heartier than the general older population. IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Crim A, Rowland M, Ruskin R, et al. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017. PMID: 28583323. doi:10.1016/j.ygyno.2017.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。